Active Ingredient History
Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Heart Failure (approved 1981)
Anemia, Sickle Cell (Phase 2)
Anesthesia (Phase 1/Phase 2)
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Angina, Unstable (Phase 4)
Arterial Occlusive Diseases (Phase 3)
Arthritis, Rheumatoid (Phase 3)
Atherosclerosis (Phase 3)
Autoimmune Diseases (Phase 3)
Biliary Tract Diseases (Phase 2)
Bone Diseases, Metabolic (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cardiac Catheterization (Phase 3)
Cardiopulmonary Bypass (Phase 4)
Cardiovascular Diseases (Phase 4)
Catheter-Related Infections (Phase 1/Phase 2)
Cerebral Hemorrhage (Phase 2)
Chest Pain (Phase 2)
Cholangiopancreatography, Endoscopic Retrograde (Phase 2/Phase 3)
Colic (Phase 2)
Colonic Polyps (Early Phase 1)
Colorectal Neoplasms (Early Phase 1)
Contraception (Phase 4)
Coronary Artery Bypass (Phase 4)
Coronary Disease (Phase 4)
Diabetes Mellitus (Phase 2)
Erectile Dysfunction (Phase 3)
Escherichia coli Infections (Phase 4)
Esophageal Diseases (Phase 4)
Extracorporeal Membrane Oxygenation (Phase 2)
Fissure in Ano (Phase 4)
General Surgery (Phase 4)
Gynecomastia (Phase 3)
Hand Injuries (Phase 3)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Heart Transplantation (Phase 4)
Hypertension ()
Hypertension, Pulmonary (Phase 1)
Hypertrophy, Left Ventricular (Phase 2)
Hypotension (Phase 4)
Inflammation (Phase 1)
Intrauterine Devices (Phase 4)
Ischemic Stroke (Phase 3)
Kidney Diseases (Phase 4)
Labor, Obstetric (Phase 4)
Lung Neoplasms (Phase 2)
Medicine, Chinese Traditional (Phase 4)
Menopause (Phase 2)
Microcirculation (Phase 4)
MINOCA (Phase 4)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 3)
Myocardial Reperfusion Injury (Phase 3)
Osteoporosis (Phase 3)
Pain (Phase 3)
Pancreatitis (Phase 3)
Percutaneous Coronary Intervention (Phase 4)
Perfusion (Phase 4)
Peripheral Arterial Disease (Early Phase 1)
Pharmacokinetics (Early Phase 1)
Phlebitis (Phase 1/Phase 2)
Placenta, Retained (Phase 4)
Platelet-Rich Plasma (Phase 4)
Radial Artery (Phase 4)
Raynaud Disease (Phase 3)
Rectal Neoplasms (Phase 1)
Regional Blood Flow (Phase 4)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Retina (Phase 4)
Scleroderma, Systemic (Phase 3)
Sepsis (Phase 4)
Shock (Early Phase 1)
Shock, Hemorrhagic (Phase 2)
Shock, Septic (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Spasm (Phase 2/Phase 3)
ST Elevation Myocardial Infarction (Phase 4)
Stroke (Phase 3)
Tendinopathy (Phase 2)
Vascular Diseases (Phase 1/Phase 2)
Vasodilation (Phase 3)
Vasospasm, Intracranial (Phase 4)
Version, Fetal (Phase 2/Phase 3)
Wound Healing (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
